{"id":"NCT02117934","sponsor":"Dynavax Technologies Corporation","briefTitle":"Safety and Immunogenicity Study of the Hepatitis B Vaccine, HEPLISAV™, Compared to Engerix-B® Vaccine","officialTitle":"A Phase 3, Observer-Blinded, Randomized, Active-Controlled (Engerix-B), Multicenter Trial of the Safety and Immunogenicity of HEPLISAV in Adults 18 to 70 Years of Age","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-04","primaryCompletion":"2015-10","completion":"2015-10","firstPosted":"2014-04-21","resultsPosted":"2018-01-10","lastUpdate":"2019-03-20"},"enrollment":8374,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"PREVENTION"},"conditions":["Healthy"],"interventions":[{"type":"BIOLOGICAL","name":"HEPLISAV","otherNames":["Hepatitis B vaccine (recombinant), adjuvanted","HEPLISAV-B"]},{"type":"BIOLOGICAL","name":"Engerix-B","otherNames":["Hepatitis B vaccine (recombinant)"]}],"arms":[{"label":"HEPLISAV","type":"EXPERIMENTAL"},{"label":"Engerix-B","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of the study is to evaluate the safety and immunogenicity of an investigational hepatitis B vaccine (HEPLISAV) in adults 18 to 70 years of age.","primaryOutcome":{"measure":"Percentage of Subjects Reporting Clinically Significant Adverse Events - Medically-attended Adverse Events, Serious Adverse Events, and Immune-mediated Adverse Events of Special Interest","timeFrame":"Week 56","effectByArm":[{"arm":"HEPLISAV","deltaMin":0.1,"sd":null},{"arm":"Engerix-B","deltaMin":0.04,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":4,"exclusionCount":8},"locations":{"siteCount":40,"countries":["United States"]},"refs":{"pmids":["31431412","29289383"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":345,"n":5587},"commonTop":["Upper respiratory tract infection","Bronchitis","Sinusitis","Urinary tract infection","Hypertension"]}}